|
- Setmelanotide - Wikipedia
Setmelanotide, sold under the brand name Imcivree, is a medication used for the treatment of genetic obesity caused by a rare single-gene mutation [4][5][6]
- IMCIVREE® (setmelanotide) injection
Discover IMCIVREE® (setmelanotide) injection, the first and only FDA-approved treatment to target an impaired MC4R pathway, a root cause of hunger and obesity in people living with Bardet-Biedl syndrome (BBS), or POMC, PCSK1, or LEPR deficiency
- Setmelanotide Uses, Side Effects Warnings - Drugs. com
What is setmelanotide? Setmelanotide is used to help with weight loss and control of hunger in people with certain genetic deficiencies who are 6 years and older
- Setmelanotide (subcutaneous route) - Side effects dosage
Setmelanotide injection is used to help lose weight and keep the weight off in patients with obesity caused by proopiomelanocortin (POMC), proprotein convertase subtilisin kexin type 1 (PCSK1), leptin receptor (LEPR) deficiency, or Bardet-Biedl syndrome (BBS)
- Setmelanotide Injection: MedlinePlus Drug Information
Setmelanotide injection is used to lose weight and then to keep from gaining back that weight in those individuals who are obese due to certain inherited conditions Setmelanotide is in a class of medications called melanocortin 4 (MC4) receptor agonists
- Setmelanotide: A Melanocortin-4 Receptor Agonist for the Treatment of . . .
The emergence of a new therapeutic treatment, the melanocortin-4 receptor agonist setmelanotide (originally RM-493), has represented a breakthrough in the management of monogenic obesity and has raised hope in managing complex obesity
- FDA approves first treatment for weight management
[11 27 2020] The U S Food and Drug Administration approved Imcivree (setmelanotide) for chronic weight management (weight loss and weight maintenance for at least one year) in patients six years
- Setmelanotide: Uses, Interactions, Mechanism of Action | DrugBank Online
Setmelanotide is a drug indicated to treat obesity caused by genetic POMC, PCSK1, or LEPR deficiencies or Bardet-Biedl syndrome
|
|
|